Innovative Cardiovascular Solutions (ICS), a Kalamazoo, MI-based clinical stage company, completed a $5M Series B funding.
The proceeds will be used for device development and initiation of a 510(k) clinical study in the U.S.
Led by R. Kevin Plemmons, co-founder and CEO, Innovative Cardiovascular Solutions is currently developing the EMBLOK™ Embolic Protection System which is designed for use in Transcatheter Aortic Valve Replacement (TAVR) and other structural heart procedures where embolic protection is required.
The EMBLOK system is an embolic protection device designed to offer complete circumferential aortic collection while protecting the cerebral, abdominal and peripheral vasculature from liberated embolic debris. In addition, the system features an integrated 4 Fr radiopaque pigtail catheter which provides the physician constant visualization, while eliminating the need for unnecessary dye injections to verify positioning.
The entire system is 11 Fr and allows two devices (i.e., embolic filter and pigtail catheter) to be deployed through a single femoral puncture site.